Surface Oncology, Inc.
SURFDelisted Sep 8, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001718108
Surface Oncology, Inc. was delisted on Sep 8, 2023; its insiders filed their last Form 4 on Sep 8, 2023; 62 institutions reported holding it in 13F filings for Q2 2023, worth $16.9M in total; ARK Invest was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 62
- Q2 2023, −10 vs. previous quarter
- 13F value
- $16.9M
- Reported value at the end of Q2 2023
- Superinvestors holding
- 1
- At the end of Q2 2023
Superinvestors holding SURF, Q2 2023
1 superinvestor reports holding Surface Oncology, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Surface Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Oneill AlisonChief Medical Officer | SSale | −7.04K | $0.94 | −$6.62K | −11.1%56.7K after | |
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Adams ChandraDeputy GC | SSale | −3.90K | $0.94 | −$3.67K | −11.2%30.9K after | |
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Fees JessicaChief Financial Officer | SSale | −9.43K | $0.94 | −$8.87K | −8.5%101.9K after | |
| Aug 11, 2023 (view filing) | Aug 1 | 10 daysLate | Ross Robert W.Chief Executive Officer | SSale | −16.7K | $0.94 | −$15.7K | −16.7%83.2K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Rath Henry C.Chief Business Officer | SSale | −5.68K | $1.72 | −$9.76K | −14.9%32.3K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Oneill AlisonChief Medical Officer | SSale | −4.46K | $1.72 | −$7.68K | −6.5%63.7K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Ross Robert W.Chief Executive Officer | SSale | −10.6K | $1.72 | −$18.2K | −9.6%99.9K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Fees JessicaChief Financial Officer | SSale | −5.98K | $1.72 | −$10.3K | −5.1%111.3K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Palombella Vito J.Chief Scientific Officer | SSale | −4.46K | $1.72 | −$7.68K | −4.9%87.2K after | |
| Jan 14, 2022 (view filing) | Jul 21, 2021 | 177 daysLate | Goater JeffDirector | SSale | −127.8K | $6.10 | −$779.4K | −49.7%129.2K after |
Top 10 13F holders, Q2 2023
The largest institutional positions in Surface Oncology, Inc. at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 4,890,000 | $4.25M | 0.11% | +4,890,000 | New |
| Atlas Venture Associates IX, LLC | 2,945,453 | $2.56M | 14.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,309,286 | $2.01M | 0.00% | 00.0% | Unchanged |
| ARK Investment Management LLCSuperinvestorARK Invest | 1,412,077 | $1.23M | 0.01% | −4,084,069−74.3% | Reduced |
| DAFNA Capital Management LLC | 1,100,000 | $956.6K | 0.26% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 868,620 | $754.0K | 0.00% | −183,098−17.4% | Reduced |
| Yakira Capital Management, Inc. | 785,879 | $683.4K | 0.18% | +785,879 | New |
| Geode Capital Management, LLC | 667,418 | $580.4K | 0.00% | +273,106+69.3% | Added |
| Laurion Capital Management LP | 665,400 | $578.6K | 0.02% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 567,400 | $493.0K | 0.00% | −67,600−10.6% | Reduced |